drugset / Trial / NCT05667714
Efficacy and Safety of SA58 Nasal Spray in Close Contact With COVID-19 People
RandomizedParallel-groupSingle-blindPrevention
Summary
This is a randomized, single-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of SA58 nasal spray in close contact with COVID-19 people.
Timeline
- Start
- 2022-11-26
- Primary completion
- 2022-12-30
- Completion
- 2023-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SA58 | Protein / enzyme biologic | 5 mg/ml | Intranasal |